...
首页> 外文期刊>American Journal of Surgical Pathology >SMARCA4-deficient Uterine Sarcoma and Undifferentiated Endometrial Carcinoma Are Distinct Clinicopathologic Entities
【24h】

SMARCA4-deficient Uterine Sarcoma and Undifferentiated Endometrial Carcinoma Are Distinct Clinicopathologic Entities

机译:Smarca4缺陷的子宫肉瘤和未分化的子宫内膜癌是明显的临床病理实体

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Undifferentiated and dedifferentiated endometrial carcinomas (UDEC) are aggressive uterine tumors which may show loss of expression of SMARCA4 (BRG1) or SMARCB1 (INI-1). The recently described SMARCA4-deficient undifferentiated uterine sarcoma (SDUS) has a morphology which overlaps with UDEC. In this study, we compared clinical, morphologic, immunohistochemical, and molecular characteristics to identify features which differentiate SDUS from UDEC. Cases of SDUS (n=12) were compared with cases of UDEC (n=84, 55 of which were previously published). Immunohistochemistry was performed for p53, mismatch repair proteins, claudin-4, SMARCA4, and SMARCB1. Targeted molecular profiling was performed on 15 cases. Patients with SDUS were significantly younger than those with UDEC (mean 35.8 vs. 61.2 y, P=0.0001). UDEC and SDUS showed morphologic overlap; however, phyllodiform architecture favored a diagnosis of SDUS (36% vs. 0%, P=0.005), while prominent nuclear pleomorphism was only seen in some cases of UDEC (0% vs. 24%, P=0.15). Compared with SDUS, UDEC more frequently showed TP53 mutations (0% vs. 34%, P=0.03), microsatellite instability (0% vs. 44%, P=0.006), and intact SMARCA4 and SMARCB1 (0% vs. 80%); a panel combining these immunohistochemical markers had a sensitivity of 100% and specificity of 92% in distinguishing SDUS and UDEC. Cases of UDEC had mutations in genes associated with endometrial adenocarcinomas (eg, TP53, PTEN, PIK3CA) and occasionally SMARCA4, while SDUS was characterized solely by inactivating mutations in SMARCA4. Disease-specific survival was shorter in SDUS than UDEC (median survival 9 and 36 mo, P=0.01). In conclusion, SDUS occurs in younger patients than UDEC, has a worse prognosis, and in most cases has a distinct molecular and immunohistochemical profile.
机译:未分化化的和去分化的子宫内膜癌(UDEC)是侵袭性子宫肿瘤,其可能显示SMARCA4(BRG1)或SMARCB1(INI-1)表达的丧失。最近描述的Smarca4缺陷的未分子化子宫肉瘤(SDU)具有与UDEC重叠的形态。在这项研究中,我们比较了临床,形态学,免疫组织化学和分子特征,以鉴定与UDEC分化SDU的特征。将SDUS(n = 12)的病例与UDEC(n = 84,55的案例进行了比较。针对P53,失配蛋白,克劳德蛋白-4,Smarca4和Smarcb1进行免疫组化。在15例中进行靶向分子分析。患有SDU的患者比udec的患者显着较小(平均35.8 vs.61.2 y,p = 0.0001)。 udec和sdus显示形态重叠;然而,Phyllodiform架构赞成SDU的诊断(36%对0%,P = 0.005),而在某些UDEC的情况下仅在某些情况下看到突出的核渗透性(0%对24%,P = 0.15)。与SDU相比,UDEC更频繁地显示TP53突变(0%对34%,P = 0.03),微卫星不稳定性(0%对44%,P = 0.006),并完整SMARCA4和SMARCB1(0%与80%) );结合这些免疫组织化学标记物的面板在区分SDU和UDEC时具有100%和92%的特异性的敏感性。 UDEC的病例在与子宫内膜腺癌(例如,TP53,PTEN,PIK3CA)和偶尔SMARCA4相关的基因中突变,而SDUS仅通过灭活SMARCA4中的突变表征。 SDUS的疾病特异性存活率比UDEC(中位存活9和36 MO,P = 0.01)。总之,SDU发生在较年轻的患者中,比UDEC更差,并且在大多数情况下具有不同的分子和免疫组织化学曲线。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号